AAV and lentiviral titer determination - past, present, and future

John Bechill, PhD is a Principal Scientist at Modalis Therapeutics within the Bioprocess group. In the Bioprocess group, he leads the analytical group which supports upstream and downstream AAV production. The analytics team focuses on methods of AAV characterization including AAV tittering, residual impurity measurements, and potency assay development. He received his PhD in Molecular Biology from Loyola University, and his career has focused on the development of analytical assays to characterize viral propagation.

Peng Wang earned his doctorate in Chemical and Biomolecular Engineering from UCLA in 2013. After his postdoctoral training at Harvard University in the Department of Chemistry and Chemical Biology, he worked as Senior Research Scientist at MD Anderson Cancer Center. In his current role as Senior Scientist at Lonza Research and Development Team, he is leading an analytics team to develop platform assays for AAV, Lenti and, Exosome products.

Mark White has played a key role in the development of multiple core technology capabilities and assays alongside a multidisciplinary team of biologists and engineers at Bio-Rad and previously at Berkeley Lights Inc. Mark obtained his PhD in Biomedical Sciences at the University of California, San Francisco.